IWC holdings

Computed by this site from the fund's SEC Form N-PORT filing; what the measure does not tell you · every fund in one table · hold it with other funds? X-ray the mix. Pricing: 99.99% at a quoted market price (level 1), 13 issuer countries.

IWC's largest investment is Ouster Inc at 0.86% of net assets. Penguin Solutions Inc and Sellas Life Sciences Group Inc follow; the three together are 2.32%. Ten companies are 5.46% of the fund; the other 1,372 share the rest. Among the 721 equity funds measured here, IWC behaves like 572.6 holdings against a median of 42.4 — 13.5 times the median. Across 28 quarterly filings IWC has become more concentrated: it behaved like 749.2 at 2019-09-30 and 572.6 at 2026-06-30. Between the 2026-03-31 and 2026-06-30 filings 256 positions were added and 184 dropped; 34.6% of the weight moved.

Each sentence is read from the fund's own SEC filing; the class median is computed across the comparable equity funds on this site. Nothing here is a view on the fund.

Between 2019-09-30 and 2026-06-30, IWC went from behaving like 749.2 equally weighted positions to 572.6 — 24% fewer, while its top ten went from 3.32% to 5.46% of net assets. Read across the funds on the concentration-over-time table.

One row per filed reporting period, newest first, read from EDGAR. Quarterly because that is the public filing cadence. Rows marked * are published but held out of the comparison above; the methodology page says when and why.

IWC's filing lists 1,383 positions including 18.69% of net assets in securities-lending cash collateral. Counted as filed the fund reads 27.3 effective holdings with a top ten of 23.76%; on its own investments — the figure above — it reads 572.6 with a top ten of 5.46%. The collateral is matched by a liability and is not a holding the fund chose; since 2026-09-18 every figure on this site sets it aside (methodology). Both numbers are in the data.

The 15 largest of 1,382 positions in IWC's Form N-PORT, weight as a share of net assets, securities-lending collateral excluded. Every position, every quarter: listed with the point-in-time files, available on request.

Share of IWC's own investments by the issuer country the filer reported (incorporation, not revenue). Each country links to every fund that holds it.

Monthly total returns from Item B.5 of IWC's own filings, 84 months on record. Not computed here and not from a price feed.

Cross-checked against a series computed separately from prices: median difference 0.16 percentage points over 84 months, which is roughly the distributions. Every month with the filing it came from: IWC.json · all funds.

The fund lends its holdings, and Item B.4.a of the filing names every firm holding them. At 2026-06-30, $288m was out to 27 borrowers, 18.95% of net assets. The largest, JP MORGAN SECURITIES LLC, held 28.8% of it.

Cash collateral reported against the loan: 18.69% of net assets, 98.6% of the amount lent. That is a floor on the collateral, not the whole of it — collateral the fund does not hold as a position is not in this filing, so a figure under 100% is not evidence of under-collateralisation. How that figure behaves across all funds. Every quarter IWC has filed, with each borrower: IWC.json · all funds.

1,302 positions became 1,374: 256 added (8.7% of the fund at the later date), 184 dropped (33.2% at the earlier date). Half the sum of all weight changes, a turnover proxy: 34.6%. Positions are matched on identifiers, so a security whose identifier changed shows as one drop and one add. Every filing of IWC compared this way, as a feed: changes.xml · all funds: filings received.

New: Hyperliquid Strategies, Inc. (0.22%), Realloys, Inc. (0.18%), Canadian Solar, Inc. (0.17%), Vor BioPharma, Inc. (0.15%), CytomX Therapeutics, Inc. (0.15%), Relmada Therapeutics, Inc. (0.14%). Gone: Praxis Precision Medicines, Inc. (1.73%), Applied Digital Corp. (1.17%), Applied Optoelectronics, Inc. (1.16%), Cogent Biosciences, Inc. (1.14%), Terns Pharmaceuticals, Inc. (1.05%), Terawulf, Inc. (0.93%).

84.10% equity, 15.89% short-term investment as filed; 100.0% carried at a quoted market price (fair-value level 1), 0.0% at level 3. Categories and levels are the filer's; what a low level-1 share does and does not mean is in the measure's page.

A position count cannot describe a fund that uses derivatives, because a swap is filed at its unrealised gain, not its exposure. These are the notionals the fund itself reported, against net assets of $1.52B. Notional of an interest-rate or currency swap is not equity exposure.

Full detail for every fund that files derivatives: leverage.json (CC BY 4.0).

Every measured equity fund lined up by how many holdings it behaves like; these sit either side of IWC (572.6). Same filings, same arithmetic. Position in this list says nothing about which fund is better.